Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

The STAT2 trial used a combination of the Biolife Statseal potassium ferrate hemostatic patch and a Terumo TR Band to reduce radial access arteriotomy site hemostasis by 50 percent.

News | Radial Access | Dave Fornell, Editor

Radial Hemostasis Time Cut by 50 Percent With StatSeal in Combination With TR Band

April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to ...

April 28, 2021

Videos | Cardiogenic Shock

VIDEO: Final Results of the National Cardiogenic Shock Initiative Show 71 Percent Survival

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...

April 28, 2021

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images

News | Cath Lab

COVID Caused Major Decline in Heart Attack Patients Seeking Care

April 28, 2021 – Results from a retrospective observational study, presented today at Society for Cardiovascular ...

April 28, 2021

Sponsored Content

Blog | Contrast Media Injectors

BLOG: Enhancing Efficiency and Patient Care with a Modern Injector

Adjustable parameters on the ACIST® CVI® Contrast Delivery System include, flow rate, volume, pressure limit, rise time ...

August 22, 2023

A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab

SCAI Updates Best Practices in the Cardiac Cath Lab Guidelines Document

April 28, 2021 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus ...

April 28, 2021

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Feature | Structural Heart

Advice For Hospitals Starting a Structural Heart Program

The resounding success of transcatheter aortic valve replacement (TAVR) has led the creation of hundreds of structural ...

April 22, 2021

The FDA’s market clearance occurred once the agency reviewed EnsiteVascular’s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure. Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.

News | Hemostasis Management

FDA Clears SiteSeal SV Vascular Closure Device for the Brachial Arteries

April 21, 2021 — EnsiteVascular announced it received its second U.S. Food and Drug Administration (FDA) market ...

April 21, 2021

Sponsored Content

As medical advancements continue to push the boundaries of what is possible in the field of structural heart interventions, the importance of enterprise imaging has become increasingly evident.

Blog | Enterprise Imaging

BLOG: The Power of Enterprise Imaging in Structural Heart Procedures

As medical advancements continue to push the boundaries of what is possible in the field of structural heart ...

August 10, 2023

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Blog | Structural Heart

Creating a Structural Heart Program is an Investment in the Future of the Hospital

As a medical technology journalist, a little more than a decade ago I found myself sitting in those late afternoon ...

April 21, 2021

News

North American COVID-19 STEMI Research Reveals High Mortality and Atypical Symptoms

April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the ...

April 20, 2021

The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

News | Structural Heart Occluders

Bioresorbable ASD Occluder Prepares to Enter U.S. Clinical Trial

April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...

April 20, 2021

Sponsored Content

While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the wealth of technological advancements, bringing the necessary tools together in a streamlined workflow has remained a challenge for clinicians

Case Study | Baylor Scott and White Heart Hospital

Contemporary PCI: Utilizing State-of-the-Art Technology to Achieve the Best Outcomes

While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the ...

May 05, 2023

The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.

News | Stents

First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology

April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...

April 14, 2021

The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal transseptal crossing devices. This is the only transseptal puncture system specifically engineered to pair and mate seamlessly with Acutus’ own suite of sheaths and with sheaths sold by other manufacturers.

News | EP Lab

FDA Clears Acutus Medical AcQCross Suite of Transseptal Crossing Devices

April 14, 2021 — The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal ...

April 14, 2021

The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR).

News | Structural Heart

Abbott Receives CE Mark and Canadian Approval for Next-Generation TriClip Tricuspid Valve Repair Device

April 8, 2021 — Abbott today announced it has received European CE mark and Health Canada authorization this week for ...

April 08, 2021

Sponsored Content

Blog | Intra-Vascular Ultrasound (IVUS)

BLOG: Making a Case for the Variable Rate Contrast Injector

During cardiology fellowship, my institution had a hand manifold system. I found it difficult to use at times, and it ...

April 11, 2023

A reconstructed vessel segment from a cone-beam CT created table side in the cath lab with the Philips Azurion SmartCT software.

News | Angiography

Philips SmartCT Enables 3D Image Acquisition in the Cath Lab

April 7, 2021 — Philips Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Philips ...

April 07, 2021

Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

News | Stroke

Thrombectomy Market Will Grow With Newly Approved Adjustable Stent Retriever

April 7, 2021 — Market research firm GlobalData's new report, Neurovascular Thrombectomy Devices (Neurology Devices), sh ...

April 07, 2021

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2]

News | Stents

Abbott’s Xience Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy for High Bleeding Risk Patients

April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti ...

April 06, 2021